There are no announcements yet.
Human immunodeficiency virus, or HIV, is the virus that causes acquired immune deficiency syndrome (AIDS). The virus weakens a person’s immune system so they are not able to fight infections or cancer as effectively. Having HIV does not always mean you have AIDS, as it can take many years for people with HIV to develop AIDS.
HIV targets a type of white blood cell called a CD4 cell, which it attacks and destroys. CD4 cells are important for fighting disease, and when a person’s CD4 cell count is too low, they are more susceptible to illness.
HIV is contracted when infected bodily fluids such as blood, semen, fluids from the vagina, or breast milk enter a person’s blood stream. It is commonly a sexually transmitted disease, but can occur when needles are not cleaned properly or are shared. It can also enter the body through broken skin. In addition, a pregnant woman with HIV can spread the virus to her baby.
Symptoms of HIV generally appear after a person’s immune system has been weakened. The symptoms are:
Fatigue and lack of energy
Unexplained weight loss
Frequent fevers or sweats
Persistent or frequent yeast infections
Persistent skin rashes
Short term memory loss
Mouth, genital, or anal sores from herpes infections
Once a person develops AIDS, meaning their CD4+ cell count is below 200 per microliter of blood, the whole body and nearly every organ can be affected. The person can have the following symptoms:
Cough/shortness of breath
Seizures
Difficult or painful swallowing
Mental symptoms (confusion, forgetfulness)
Severe and persistent diarrhea
Fever
Vision loss
Nausea, abdominal cramps, bloating
Weight loss and extreme fatigue
Severe headaches
Coma
HIV/AIDS medications are very powerful and often produce powerful side effects. They include:
Anemia
Diarrhea and abdominal pain
Nausea
Vomiting
Fatigue
Dizziness
Chills
Anxiety
Rash
Depression
Difficulty sleeping
Headache
While the effects of cannabinoids have not been studied for all of these symptoms and side effects, there are many reports that cannabinoids can be beneficial, either lessening the symptoms of the disease itself, or the side effects of the medication. Cannabinoid solutions seems to have a positive effect on stomach upset, abdominal pain, nausea/vomiting, difficulty sleeping, anxiety, and headaches.
In addition, TAT (Trans-Activator of Transcription), an HIV gene, has been shown by researchers at the Mount Sinai School of Medicine to be inhibited by cannabinoids. HIV has been able to mutate and reproduce itself despite the use of antiretroviral drugs. Soon, the HIV in countless numbers of patients will be resistant to conventional treatments, a huge problem for the whole world. Cannabis Science has begun a drug development program to target this problem, using cannabinoids to inhibit TAT.
Cannabis Sciences’s work with cannabinoids in relation to HIV/AIDS will create more scientific studies and information for the public and medical community’s general knowledge about cannabinoid solutions.
Recent GBXI News:
May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets
April 21, 2023, GBX International Group, Inc., (OTC: GBXI)
HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Hi Raymond,
As a long-standing Loyal Shareholder, I hope that this posting finds you in good health and good spirits. I made my first CBIS purchase...Hi Raymond,
As a long-standing Loyal Shareholder, I hope that this posting finds you in good health and good spirits. I made my first CBIS purchase in Sept 2014 (Dr. Bob was still at CBIS) and I made my last purchase in June 2017; just prior to the Hemp Seizure that F'k-up everything for CBIS going forward.
BUT, on 2017-01-09 CBIS Entered into 1 yr. Research Collaboration Agreement (RCA) with Dana Farber Cancer Institute (DFCI) to Develop Cannabinoid-Based Medications and Associated Delivery Technologies for the Treatment of Cancers.
Then on 2018-01-18 1st Frontiers In Oncology Article: "Nano Particle Drone to Target Lung Cancer with Radio Sensitizers & Cannabis." - KILLING CANCER
And then again on 2018-02-02 CBIS expanded the RCA with DFCI for 5 yrs. (@ $1.8M) to develop Cannabinoid-Based Medications and Associated Delivery Technologies for the Treatment of Cancers. That RCA agreement expired on 2023-02-02.
NOW, On 2023-02-02 the Expanded RCA with DFCI has ended. THE RESULTS ARE NOW KNOWN:
For the $1.8mil investment with DFCI, several Cancer Killing Formulations have been developed.
#1-6 Represents the drug formulations developed by DFCI during the 5yr RCA for treatment of the following cancers:
1. Skin Cancer
2. Breast Cancer
3. Brain Cancer
4. Kaposi's Sarcoma
5. Lung Cancer
6. Pancreatic Cancer
7. CBN Patent Valuation
#7 is the US Patent that was awarded to CBIS which describes the formulation used to treat certain neurological ailments such as ODD, ADD, etc.
On 2023-05-08 it was announced that GBXI signs the first 3 acquisitions for the GBXI Conglomerate (follow link below for details)
finance.yahoo.com/news/gbxi-advances-forward-signs…
Then On 2023-12-13 you posted the following: "GBXI Corporate Filings, Financials, and trading status has been delayed due to change of control filings and approvals. The Company has several options on the list for trading resumption as it pursues its regulatory approvals. The Company is pursuing the fastest path to trading first and will proceed down the list as it moves towards its ultimate goal of bringing all the GBXI conglomerate company shares back trading again.
QUESTION: Where are we toward the completion of this process?? 50% / 75% / 90% ????
--------
Some info that the I have found about a SPAC is as follows:
When does a SPAC become public?
--------------------------------------------
These types of transactions, most commonly where a SPAC acquires or merges with a private company, occur after, often many months or more than a year after, the SPAC has completed its own IPO. Unlike an operating company that becomes public through a traditional IPO, however, a SPAC is a shell company when it becomes public.
Period to consummate the initial business combination.
--------------------------------------------------------------------
A SPAC will typically provide for a two-year period to identify and complete an initial business combination transaction. However, some SPACs have opted for shorter periods, such as 18 months. The SPAC’s governing instruments may permit it to extend that time period. If a SPAC seeks to extend the time period, it may be required to seek shareholder approval. If a SPAC lists its securities on an exchange, it is required to complete an initial business combination within three years of its IPO. IPO proceeds are held in the trust account until a SPAC consummates a business combination or liquidates. If the SPAC is liquidated, shareholders at the time of the liquidation will be entitled to their pro rata share of the aggregate amount then on deposit in the trust account.
On 2023-11-08 an independent entity named Capizate, Inc.; prepared and presented a "Situation Analysis of the GBX International Group" which provided a list of Strengths, Areas of Improvements, and a Cancer Drug Valuation of just one of the drug formulations noted above ($25Mil-$29Mil) - Impressive.
However, here is the list that I have concern for; can't go PUBLIC without being fixed:
Areas for improvement
----------------------------
1. The business documents, agreements, term sheets, engagements are all dated in 2017-2018 and need to be updated.
2. Ownership and control of the intellectual property needs to be defined and confirmed.
3. A similar entity has active registration with California Secretary of State. The Company has a different address than on the Company website and also had a Statement of Info due to the California Secretary of State on 05/10/2023. Registered with the California Secretary of State as a Non-Profit Nonprofit Corporation - CA - Mutual Benefit. This will need to be defined.
QUESTIONS:
---------------
(1) Who's working on updating documentation? What's the % complete?
(2) Who owns and/or controls the CBIS Intellectual Property?
(3) is there another entity out there using the same name as Cannabis Science?
(4) WHERE IS BRINGING CBIS BACK PUBLIC AGAIN ON YOUR LIST OF PRIORITIES?
Thank you Raymond in advance of your response.
Best Regards
Show more
CBIS’s beautiful, state-of-the-art, retail facilities are designed to connect Cannabis Science directly with patients and doctors. They showcase...
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
1. Original CBIS, everyone has... Show more 7 hours 41 minutes ago